LOGIN
Significant reduction in 6-year fragility fracture risk with zoledronate vs placebo for osteopenia
April 2019
Significant reduction in 6-year fragility fracture risk with zoledronate vs placebo for osteopenia
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:N/A
Fracture Prevention with Zoledronate in Older Women with Osteopenia
N Engl J Med. 2018 Dec 20;379(25):2407-2416. doi: 10.1056/NEJMoa1808082Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
2000 postmenopausal women with osteopenia were randomized to treatment with infusion of either zoledronate 5mg or placebo every 18 months for 6 years. Participants were assessed for incidence of fractures, prespecified adverse events including mortality, vascular events, cancer, and osteonecrosis of the jaw, and bone mineral density after 6 years. Results demonstrated significantly lower incidence...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
The OE High Impact metric uses AI to determine the impact a study will have by considering the content of the article itself. Built using the latest advances of natural language processing techniques. OE High Impact predicts an article’s future number of citations than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.